Research chemicalResearch chemicalPsychedelicLysergamide

1V-LSD (Valerie)

Also known as Valerie · 1-valeryl-LSD

Written by enwyReviewed 15 Jul 20261 sources0 comments

1V-LSD is a valeryl (pentanoyl) prodrug of LSD, developed largely to sidestep the 2021 German NpSG blanket ban that captured 1P-LSD and 1cP-LSD. It is assumed to hydrolyse to LSD in the body, producing an essentially LSD-like psychedelic experience. It has no clinical study base.

01 Overview

1V-LSD is a semi-synthetic lysergamide sold on the European research-chemical market as blotters and pipettes, nicknamed "Valerie" for its N1-valeryl substituent. Like other 1-acyl LSD analogues, it is understood to act as a prodrug that is cleaved to LSD, so users report a duration, visual character and headspace close to LSD itself.

There are no controlled human trials of 1V-LSD; all potency and duration figures come from user reports and analogy to LSD. Because the same total dose of active drug is ultimately delivered, the safety considerations of LSD apply: psychological destabilisation, HPPD risk, and dangerous behaviour during acute intoxication.

02 Mechanism

Presumed prodrug hydrolysed in vivo to LSD, which acts as a partial agonist at 5-HT2A (and other serotonin) receptors to produce psychedelic effects.

03 Dosing

Tier	Dose	Route	Notes
Threshold	10–20 mcg	Sublingual	Sub-perceptual to microdose range.
Common	75–150 mcg	Sublingual	Full psychedelic dose; roughly LSD-equivalent.
Strong	150–250 mcg	Oral	Intense visuals and ego dissolution.

04 Effects

Effect	Magnitude	Evidence
Visual and sensory alterationGeometric visuals, colour enhancement and altered perception, reported as LSD-like.	8-12 h	Anecdotal
Mood elevation and introspectionEuphoria, emotional openness and shifts in thought associated with 5-HT2A agonism.		Anecdotal
Anxiety / challenging experienceFear, paranoia or confusion, more likely at high doses or in poor set and setting.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Sympathomimetic effectsRaised heart rate and blood pressure, mydriasis and mild tremor.	Mild	Common	Anecdotal
Acute anxiety and psychological distressPanic, paranoia or a distressing "bad trip" during acute effects.	Moderate	Common	Anecdotal
Persistent perceptual changes (HPPD)Lasting visual disturbances after the drug has worn off, documented for LSD-type drugs.	Moderate	Rare	Observational

06 Legal status

Germany

NpSG (New Psychoactive Substances Act)

Brought under NpSG by later amendments closing the LSD-prodrug loophole. · as of Jan 2026

United States

Possible Schedule I analogue

May be treated as an LSD analogue under the Federal Analogue Act if intended for human consumption. · as of Jan 2026

07 References

Lysergic acid diethylamide (LSD) pharmacology and clinical researchPubMed search

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.